tirzepatide surpass Frias_Tirzepatide: Overview of Trials in Patients With Type 2 Diabetes Media Centre | EASD
Description
Recently, a 3-year study in 101 NASH patients with prediabetes/T2DM (an 18-month RCT, followed by an 18-month open-label phase with pioglitazone treatment) confirmed its long-term safety and efficacy [26]
More serious concerns can include dehydration, severe abdominal pain, allergic reaction symptoms, gallbladder problems, or low blood sugar when combined with certain diabetes medicines
12 weeks) and 6.5% (12 vs
Used with diet and exercise, this once-daily medication improves glycemic control by removing excess sugar from the body and reducing sugar production in the liver
Conclusions These findings suggest a potentially elevated risk of vision impairment with semaglutide use compared to other diabetes and weight loss medications, warranting further investigation and vigilant post-marketing surveillance
Ivana Posey, a nurse practitioner at Infinity Meadows Spa, says people taking GLP-1 medications should be especially mindful of their water intake
